December 19, 2022
Another great event by Recipharm organized by Helen Domeshek,PhD! Thank you for this fun and informative evening 🍻 Great opportunity to discuss with colleagues and friends about #fundraising #ipo #croudfunding #bussinessdevelopment and more! Great job by our CEO Dr. Lior Shaltiel, PhD telling NurExone Biologic‘s story Read More …
NurExone Biologic Ltd., an Israeli biopharmaceutical company aiming to revolutionize the treatment of spinal cord injury (SCI), is leveraging its proprietary technologies into a platform technology company with a potentially diverse portfolio of novel, cutting-edge therapies for several CNS traumatic indications. Read More …
We started our journey to provide much-needed therapy for people who have suffered spinal cord injuries and have accomplished very significant achievements in 2022. As we progress with developing our underlying technology, the awareness of a greater picture has intensified. The same technologies and science that will serve NurExone may
The Company agreed to settle debts in the aggregate amount of CAD$46,523.69 with the issuance of 122,430 common shares of the Company at the market price on November 24, 2022 of CAD$0.38 per share. These debts were incurred prior to the recent Reverse Takeover Transaction following which NurExone began trading